Infectious Disease Management In Animal Shelters

Infectious Disease Management In Animal Shelters

Professional Veterinary E-Book - Instant PDF Download

Comprehensive veterinary reference covering infectious disease management in animal shelters. This digital edition provides in-depth coverage suitable for veterinarians, veterinary students, technicians, and animal health professionals.

Key Features:

• Instant digital download after purchase
• High-quality PDF format - works on all devices
• Fully searchable text for quick clinical reference
• Printable pages for study and practice use

Category: Clinical Sciences

Published by Global Vet and Co Ltd.

Table of Contents

• References (p.8)
• Contents (p.9)
• 1 Introduction (p.19)
• 2 Chemical Composition (p.22)
• 3 Turmeric Consumption (p.22)
• 4 Pharmacokinetics (p.22)
• 5 Mechanism of Action (p.23)
• 6 Digestive System (p.24)
• 7 Common Cold and Infections (p.26)
• 8 Osteoarthritis (OA, Degenerative Joint Disease) (p.26)
• 9 Pain (p.28)
• 10 Sports Medicine (p.29)
• 11 CNS Effects (p.30)
• 12 Diabetes (p.30)
• 13 Metabolic Syndrome (p.31)
• 14 Retinopathies (p.32)
• 15 Allergy (p.32)
• 16 Psoriasis (p.33)
• 17 Kidney Stones (p.33)
• 18 Cancer (p.33)
• 19 Translation from Population Epidemiology and Clinic to Bench (p.34)
• 20 Translation: Preclinical to Clinic (p.34)
• 21 Gaps and Opportunities (p.34)
• 22 Concluding Remarks and Future Directions (p.35)
• References (p.36)
• 1 Introduction (p.40)
• 2 Phytoconstituents (p.41)
• 3 Uses of Fenugreek (p.42)
• 4 Fenugreek in Animal, Poultry, and Fish Feeds (p.46)
• 5 Toxicology and Safety Profile (p.47)
• 6 Concluding Remarks and Future Directions (p.47)
• References (p.47)
• 1 Introduction (p.51)
• 2 Extracts of Neem (p.52)
• 3 Phytoconstituents (p.53)
• 4 Medicinal Uses (p.53)
• 5 Neem as Livestock Feed (p.56)
• 6 Neem as Nutraceutical (p.58)
• 7 Safety (p.59)
• 8 Toxicity (p.60)
• 9 Concluding Remarks and Future Directions (p.61)
• References (p.61)
• 1 Introduction (p.65)
• 2 Phytochemical Composition of Ginger (p.66)
• 3 Pharmacological Profile of Ginger (p.66)
• 4 Veterinary Use of Ginger (p.76)
• 5 Safety Profile of Ginger (p.77)
• 6 Concluding Remarks and Future Directions (p.78)
• References (p.78)
• 1 Introduction (p.85)
• 2 Pharmacokinetics and Pharmacodynamics (p.86)
• 3 Pharmacological and Therapeutic Potential of BBR (p.87)
• 4 Safety and Toxicity of BBR (p.92)
• 5 Concluding Remarks and Future Directions (p.92)
• References (p.93)
• 1 High-Altitude Environment (p.96)
• 2 Constraints and Prospects of Poultry Production at High-Altitude Region (p.97)
• 3 Important Diseases and Clinical Conditions of Poultry at High Altitude (p.97)
• 4 Nonconventional Sources for Poultry Feeding at High-Altitude Cold Desert (p.97)
• 5 Sea Buckthorn as a Source of Phytomolecules and Their Therapeutic Value (p.97)
• 6 Apricot as Source of Various Phytomolecules and Their Therapeutic Value (p.98)
• 7 Mechanism of Therapeutic Value of Sea Buckthorn- and Apricot-Based Nutraceuticals (p.100)
• 8 Available Sea Buckthorn and Apricot Plant-Based Feed Formulation (p.101)
• 9 Concluding Remarks and Future Directions (p.101)
• References (p.102)
• 1 Introduction (p.104)
• 2 Geographical Location (p.105)
• 3 Taxonomical Classification (p.105)
• 4 Chemical Constituents of NS (p.105)
• 5 Pharmacological Studies (p.106)
• 6 Toxicological Properties (p.111)
• 7 Concluding Remarks and Future Directions (p.111)
• References (p.111)
• 1 Introduction (p.115)
• 2 Chemical Constituents in Babool (p.115)
• 3 Nutritional Value of Babool (p.116)
• 4 Pharmacotherapeutic Effects (p.116)
• 5 Toxicity and Safety (p.120)
• 6 Concluding Remarks and Future Directions (p.120)
• References (p.120)
• 1 Introduction (p.124)
• 2 Metabolism of Glucosinolates (p.125)
• 3 Important Glucosinolates (p.125)
• 4 Effects of Glucosinolates (p.126)
• 5 Concluding Remarks and Future Directions (p.129)
• References (p.129)
• 1 Introduction (p.131)
• 2 Cannabis sativa L.: Food, Herbal Medicine, Pharmaceutical, and Nutraceutical (p.132)
• 3 Modern History of Cannabinoid Pharmacology (p.135)
• 4 Endocannabinoid (eCB) Chemistry (p.135)
• 5 Cannabis sativa Chemistry (p.143)
• 6 Animal Studies and Veterinary Clinical Trials (p.150)
• 7 Guidance on Veterinary Cannabis Products in the US Market (p.153)
• 8 Current Good Manufacturing Practices (cGMP) (p.159)
• 9 Concluding Remarks and Future Directions (p.160)
• References (p.160)
• 1 Introduction (p.166)
• 2 Essential Oils (p.171)
• 3 Essential Oils as Modifiers of Rumen Fermentation, Immune System, and Lactation (p.177)
• 4 Safety of Essential Oils (p.177)
• 5 Concluding Remarks and Future Directions (p.177)
• References (p.177)
• 1 Introduction (p.183)
• 2 Omega Fatty Acids (p.183)
• 3 Omega Fatty Acids as Nutraceuticals in Veterinary Medicine (p.184)
• 4 Potential Adverse Effects of Omega Fatty Acids in Dogs and Cats (p.191)
• 5 Concluding Remarks and Future Directions (p.191)
• References (p.191)
• 1 Introduction (p.194)
• 2 Phytochemicals (PCs) (p.195)
• 3 Classification of Nutraceuticals (p.200)
• 4 Significance of Polyphenols in Flora and Fauna and Human Health (p.200)
• 5 Polyphenols and Flavonoids in Human Medicine (p.203)
• 6 Polyphenols and Flavonoids in Veterinary Medicine (p.204)
• 7 Potential Use of Polyphenols and Flavonoid-Rich Plants in Animal Feeding (p.206)
• 8 Toxicity of Polyphenols and Flavonoids (p.207)
• 9 Concluding Remarks and Future Directions (p.207)
• References (p.208)
• 1 Introduction (p.212)
• 2 Biomarkers of Oxidative Stress (p.213)
• 3 Oxidative Stress and Neurodegeneration (p.213)
• 4 Oxidative Stress and Antioxidants in Non-neurodegenerative Diseases (p.214)
• 5 Antioxidant systems (p.214)
• 6 Concluding Remarks and Future Directions (p.217)
• References (p.217)
• 1 Prologue (p.221)
• 2 Introduction (p.221)
• 3 Relevant Biological Actions (p.224)
• 4 Pharmacological Aspects: Pharmacodynamics and Pharmacokinetics (p.228)
• 5 Adverse Effects (p.230)
• 6 Concluding Remarks and Future Directions (p.230)
• References (p.230)
• 1 Introduction (p.233)
• 2 Eggs and Eggshell Waste (p.233)
• 3 Structure of Eggshells and Membranes (p.233)
• 4 Eggshell Membranes (p.234)
• 5 Separation Methods of ESM (p.234)
• 6 Components of ESM (p.235)
• 7 Efficacy (in Humans) for Treating Joint Inflammation (p.235)
• 8 Efficacy (in Animals) for Treating Joint Inflammation and Modes of Action (p.235)
• 9 ESM as an Alternative to Antibiotics for Growth Promotion in Production Animals (p.236)
• 10 Nutritional Effects of Eggshell Membrane Supplements on Chicken Performance and Immunity (p.237)
• 11 Other Veterinary Uses of ESM (p.237)
• 12 Conclusion Remarks and Future Directions (p.237)
• References (p.238)
• 1 Introduction (p.240)
• 2 Characteristics of OVTF and LF (p.241)
• 3 OVTF and LF Receptors (p.241)
• 4 Genes of OVTF and LF (p.241)
• 5 Bioavailability of OVTF and LF (p.242)
• 6 Functional Properties of OVTF and LF (p.243)
• 7 Antibacterial Activity (p.243)
• 8 Antifungal Activity (p.244)
• 9 Antiparasitic Activity (p.244)
• 10 Antiviral Activity (p.244)
• 11 Concluding Remarks and Future Directions (p.246)
• References (p.246)
• 1 Introduction (p.249)
• 2 The Immune Response (p.249)
• 3 Veterinary Vaccines for Active Immunity (p.249)
• 4 Passive Immunity (p.250)
• 5 Antibodies (p.250)
• 6 Antibody Classes (p.250)
• 7 Antibody-Antigen Interactions (p.251)
• 8 Colostrum and Passive Immunity (p.251)
• 9 Colostrum Programs (p.253)
• 10 Vaccination of Newborn Animals While Receiving Colostrum (p.254)
• 11 Antibody Products (p.254)
• 12 Passive Immunity by Egg Antibodies (p.255)
• 13 Eggs as a Natural Source of Immunoregulatory Factors (p.255)
• 14 Monoclonal Antibodies in Veterinary Use (p.257)
• 15 Concluding Remarks and Future Directions (p.258)
• References (p.259)
• 1 Introduction (p.263)
• 2 Gastrointestinal Microbiota and Microbiome (p.263)
• 3 Classes of Alternatives to Antimicrobial Growth Promoters (p.268)
• 4 Probiotics (p.273)
• 5 Synbiotics (p.281)
• 6 Concluding Remarks and Future Directions (p.282)
• References (p.283)
• 1 Introduction (p.288)
• 2 Synbiotics for Animals (p.289)
• 3 Concluding Remarks and Future Directions (p.298)
• References (p.299)
• 1 Introduction (p.303)
• 2 Feed Enzymes and Gastrointestinal Microbiota (p.305)
• 3 Mode of Action for Enzymes (p.306)
• 4 Dietary Substrates and Enzyme Types (p.307)
• 5 Main Enzymes (p.308)
• 6 Concluding Remarks and Future Directions (p.312)
• References (p.312)
• 1 Introduction (p.314)
• 2 Impact of Phasing Out Animal Growth Promoters (p.316)
• 3 Biosecurity (p.318)
• 4 Reducing Antibiotic Use (p.322)
• 5 Gastrointestinal Microflora (p.324)
• 6 Antibacterial Alternatives in Animal Health (p.326)
• 7 Regulations Concerning Feed Additives in the European Union (p.336)
• References (p.338)
• 1 Introduction (p.343)
• 2 Classification of Animal Feed Additives (p.344)
• 3 Quality Standards for Animal Feed Additive Industry (p.354)
• References (p.358)
• 1 Introduction (p.362)
• 2 Pathophysiology of OA (p.363)
• 3 Diagnosis of OA (p.364)
• 4 Nutraceuticals in the Management of OA (p.365)
• 5 Novel Nutraceuticals (p.372)
• 6 Concluding Remarks and Future Directions (p.374)
• References (p.374)
• 1 Introduction (p.379)
• 2 Signs of Aging (p.380)
• 3 Antiaging Nutraceuticals and Functional Foods (p.382)
• 4 Concluding Remarks and Future Directions (p.386)
• References (p.386)
• 1 Introduction (p.389)
• 2 Canine Cognitive Dysfunction (p.390)
• 3 Pathophysiology (p.390)
• 4 Diagnosis of Cognition Dysfunction (p.391)
• 5 Prevention and Treatment of Cognitive Dysfunction (p.391)
• 6 Concluding Remarks and Future Directions (p.404)
• References (p.404)
• 1 Introduction (p.412)
• 2 Neurotransmitters, Neuropeptides, and HPA Axis in Stress and Anxiety (p.413)
• 3 Dietary Supplements in Calming (p.415)
• 4 Herbal Extracts in Calming (p.416)
• 5 Concluding Remarks and Future Directions (p.417)
• References (p.418)
• 1 Introduction (p.421)
• 2 Nutraceuticals Modulate Genetic Expression (p.422)
• 3 Nutraceuticals that Forestall the Development of Cardiac Dysfunction (p.422)
• 4 Soy (p.426)
• 5 Cardiac Biomarkers in Animals (p.426)
• 6 Cardiac Issues in Animals (p.426)
• 7 Concluding Remarks and Future Directions (p.427)
• References (p.428)
• 1 Introduction (p.440)
• 2 Pathophysiology of Periodontal Diseases (p.441)
• 3 Nutraceuticals in Periodontal Diseases (p.443)
• 4 Concluding Remarks and Future Directions (p.455)
• References (p.455)
• 1 Introduction (p.460)
• 2 Phytochemicals for Gastrointestinal Conditions (p.461)
• 3 Dietary Lipids and Fat-Soluble Vitamins for Gastrointestinal Conditions (p.464)
• 4 Dietary Peptides and Amino Acids for Gastrointestinal Conditions (p.465)
• 5 Probiotics, Prebiotics, and Synbiotics (p.466)
• 6 Concluding Remarks and Future Directions (p.468)
• References (p.469)
• 1 Introduction (p.473)
• 2 Nutraceutical in Female Reproductive Abnormalities (p.473)
• 3 Nutraceutical in Male Reproductive Abnormalities/Diseases (p.478)
• 4 Concluding Remarks and Future Directions (p.479)
• References (p.479)
• 1 Introduction (p.481)
• 2 Oxidative Stress in Dairy Cows (p.482)
• 3 Melatonin and Seasonal Breeders (p.483)
• 4 Herbs (p.483)
• 5 Dietary Lipids (p.485)
• 6 Carnitine (p.488)
• 7 Nutraceuticals in Assisted Reproduction (p.491)
• 8 Coconut (Cocos nucifera L.) (p.492)
• 9 Quercetin (p.493)
• 10 Vitamins and Selenium (Se) (p.494)
• 11 Ancillary Nutraceuticals (p.495)
• 12 Urinary Diseases (p.495)
• 13 Nutraceutical Recipes and Candidate Nutraceuticals (p.498)
• 14 Probiotics (p.499)
• 15 Ethnoveterinary Medicine (p.499)
• 16 Concluding Remarks and Future Directions (p.502)
• References (p.502)
• 1 Introduction (p.507)
• 2 Curcumin ((1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) (p.507)
• 3 Lagenaria siceraria (Bottle Gourd) (p.508)
• 4 Trigonella foenum-graecum (Fenugreek) (p.509)
• 5 Emblica officinalis (syn. Phyllanthus emblica; Indian Gooseberry) (p.509)
• 6 Murraya koenigii (Curry Tree) (p.509)
• 7 Vigna sp. (Black Gram, Black Lentil, Cow Pea, Black-Eyed Pea, Adzuki Bean, Mung Bean) (p.509)
• 8 Camellia sinensis (Tea) (p.510)
• 9 Hibiscus sabdariffa (p.510)
• 10 Hypericum perforatum (St. John´s Wort) (p.511)
• 11 Persea americana (Avocado) (p.511)
• 12 Capsicum annuum (Capsicum) (p.511)
• 13 Rosmarinus officinalis (Rosemary) (p.512)
• 14 Concluding Remarks and Future Directions (p.512)
• References (p.512)
• 1 Introduction (p.515)
• 2 Pathophysiology of Diabetes Mellitus (p.516)
• 3 Experimental Diabetes Models (p.516)
• 4 Diabetic Monitoring (p.517)
• 5 Prevention and Management of Diabetes in Animals (p.517)
• 6 Concluding Remarks and Future Directions (p.526)
• References (p.526)
• 1 Introduction (p.532)
• 2 Pathophysiology of Wound and Wound Healing (p.533)
• 3 Wound Healing: A New Multi-spectrum Twenty-First-Century Perspective (p.534)
• 4 Models of Wound and Wound Healing (p.534)
• 5 Formulations of Nutraceuticals and Their Delivery Systems for Wound Healing (p.537)
• 6 Nutraceuticals/Phytochemical Extracts from C. odorata for Wound Healing (p.538)
• 7 Concluding Remarks and Future Directions (p.547)
• References (p.548)
• 1 Introduction (p.554)
• 2 Nutraceuticals in Dermatitis (p.554)
• 3 Nutraceuticals in Otitis Externa (p.555)
• 4 Nutraceuticals in Infection-Associated Dermatitis (p.555)
• 5 Nutraceuticals in Allergic/Atopic Dermatitis (p.557)
• 6 Nutraceuticals in Skin (Cutaneous) Tumors (Neoplasms) (p.557)
• 7 Concluding Remarks and Future Directions (p.558)
• References (p.559)
• 1 Introduction (p.560)
• 2 Alternative Therapies (p.561)
• 3 Dry Cow Treatments (p.566)
• 4 Homeopathy (p.567)
• 5 Probiotics, Bacteriocins, and Bacteriophages (p.568)
• 6 Bacteriophages and Their Products (p.571)
• 7 Vitamin and Mineral Supplementation (p.571)
• 8 Teat Dips (p.572)
• 9 Immunotherapy (p.573)
• 10 Concluding Remarks and Future Directions (p.573)
• References (p.573)
• 1 Introduction (p.577)
• 2 Nutraceuticals in Regulation of Immune System (p.578)
• 3 Anti-inflammatory Effects of Nutraceutical (p.578)
• 4 Nutraceuticals in Degenerative and Metabolic Diseases (p.579)
• 5 Nutraceuticals in Hypersensitivity (Allergic) Disorders and Other Inflammatory Diseases (p.580)
• 6 Concluding Remarks and Future Directions (p.581)
• References (p.581)
• 1 Introduction (p.582)
• 2 Plant-Derived Immunomodulators (p.583)
• 3 Food-Derived Immunomodulators (p.585)
• 4 Clinical Applications of Food-Derived Nutraceuticals (p.589)
• 5 Concluding Remarks and Future Directions (p.589)
• References (p.589)
• 1 Introduction (p.592)
• 2 Anticancer Activities of Nutraceuticals (p.593)
• 3 Concluding Remarks and Future Directions (p.595)
• References (p.595)
• 1 Introduction (p.599)
• 2 Vitamin C in Combination with Individual Natural Compounds (p.600)
• 3 Vitamin C in Combination with Multiple Nutrients (p.602)
• 4 Green Tea Polyphenol (EGCG) in Combination with Other Natural Compounds (p.603)
• 5 EGCG in Combinations with Multiple Nutrients (p.604)
• 6 Novel Approach to Cancer Through Synergistic Combination of Vitamin C with EGCG and Other Nutrients (p.605)
• 7 Concluding Remarks and Future Directions (p.608)
• References (p.609)
• 1 Introduction (p.613)
• 2 Nutraceuticals for Control of Ticks, Fleas, and Other Ectoparasites (p.614)
• 3 Concluding Remarks and Future Directions (p.619)
• References (p.619)
• 1 Introduction (p.623)
• 2 Major Classes of Nutraceuticals Used in Cattle (p.624)
• 3 Concluding Remarks and Future Directions (p.630)
• References (p.631)
• 1 Introduction (p.635)
• 2 Regulatory Scenario (p.636)
• 3 Nutraceuticals (p.636)
• 4 Nutraceuticals as Joint Supplements (p.637)
• 5 Nutraceuticals as Performance Boosters (p.638)
• 6 The Use of Nutritional Supplements in Dressage and Eventing Horses (p.640)
• 7 Concluding Remarks and Future Directions (p.641)
• References (p.641)
• 1 Introduction (p.642)
• 2 Active Nutraceuticals (p.643)
• 3 Concluding Remarks and Future Directions (p.645)
• 1 Introduction (p.646)
• 2 Probiotics (p.647)
• 3 Prebiotics (p.648)
• 4 Synbiotics (p.649)
• 5 Exogenous Enzymes (p.650)
• 6 Organic Acids (p.651)
• 7 Polyunsaturated Fatty Acids (p.652)
• 8 Phytobiotics (p.653)
• 9 Concluding Remarks and Future Directions (p.654)
• References (p.654)
• 1 Introduction (p.660)
• 2 Toxic Actions of Nutraceuticals (p.661)
• 3 Safety and Toxicity Studies with Animal Models: Foundations, Problems, and Alternatives (p.662)
• 4 Unresolved Issues (p.665)
• References (p.666)
• 1 Introduction (p.669)
• 2 Drosophila melanogaster as a Model Organism (p.670)
• 3 Utility of Drosophila in Examining the Anticancer Potential of Nutraceuticals (p.670)
• 4 Utility of Drosophila in Examining the Efficacy of Nutraceuticals Against Aging (p.671)
• 5 Utility of Drosophila in Examining the Efficacy of Nutraceuticals Against Neurodegenerative Diseases (p.671)
• 6 Utility of Drosophila in the Toxicity Evaluation of Nutraceuticals (p.672)
• 7 Concluding Remarks and Future Directions (p.673)
• References (p.674)
• 1 Introduction (p.677)
• 2 Complexities in Food and Nutraceutical Biomarkers (p.678)
• 3 Analysis of Antioxidant Activity (p.678)
• 4 Analysis of Anti-inflammatory Activity (p.679)
• 5 Analgesic Activity (p.679)
• 6 Biomarkers of Foods and Nutraceuticals (p.679)
• 7 Biomarkers of Polyphenols and Related Compounds: A Pharmacokinetic Perspective (p.679)
• 8 Biomarkers of Toxicity and Safety Evaluation of Foods and Nutraceuticals (p.688)
• 9 Biomarkers of Nutraceuticals with Toxic Potential (p.689)
• 10 Concluding Remarks and Future Directions (p.689)
• References (p.689)
• 1 Introduction (p.695)
• 2 Hepatotoxicity (p.695)
• 3 Known Drug-Drug Interactions of Nutraceuticals (p.696)
• 4 Cardiovascular Effects (p.696)
• 5 Allergic and Skin Effects Not Associated with Hepatotoxicity (p.696)
• 6 Adverse Effects on the Coagulation System (p.701)
• 7 Adverse Effects on the Central Nervous System (p.702)
• 8 Effects on the Musculoskeletal System (p.702)
• 9 Endocrine and Reproductive System Effects (p.702)
• 10 Concluding Remarks and Future Directions (p.702)
• References (p.702)
• 1 Introduction (p.713)
• 2 Nutriproteomics (p.714)
• 3 Foodomics (p.715)
• 4 Concluding Remarks and Future Directions (p.716)
• References (p.717)
• 1 Introduction (p.719)
• 2 Advanced Matrices for Drug Vehiculation: Chemical-Physical Aspects of the Nanomaterials for Molecular Delivery (p.720)
• 3 Vesicles and Related Aggregates (p.721)
• 4 Carbon Nanotubes (p.722)
• 5 Nanomaterials as Cargos of Biological Molecules: Potential Usage in Advanced Therapeutic Strategies (p.723)
• 6 Liposomes (p.724)
• 7 Cat-Anionic Vesicles (p.724)
• 8 Nanotubes (p.725)
• 9 Concluding Remarks and Future Directions (p.726)
• References (p.727)
• 1 Introduction (p.730)
• 2 Nanosupplement Delivery (p.731)
• 3 Animal Production (p.733)
• 4 Anti-inflammatory Activity (p.740)
• 5 Immunity (p.740)
• 6 Risks and Challenges (p.742)
• 7 Concluding Remarks and Future Directions (p.742)
• References (p.742)
• 1 Introduction (p.746)
• 2 Factors That Affect Stability of Nutraceuticals (p.747)
• 3 Categories of Nutraceuticals and Their Stability (p.748)
• 4 Stability Testing Methods (p.751)
• 5 Regulatory Guideline Aspects Related to Nutraceutical Stability (p.753)
• 6 Concluding Remarks and Future Directions (p.754)
• References (p.754)
• 1 Introduction (p.757)
• 2 DSHEA (p.757)
• 3 FDA/CVM (p.758)
• 4 AFFCO (p.759)
• 5 Claims for Probiotics (p.760)
• 6 Trade Organizations Related to Veterinary Nutraceuticals (p.760)
• 7 Legally Marketing an Animal Nutraceutical in the USA (p.761)
• 8 Regulatory Rules in Different Countries for Veterinary Nutraceuticals (p.762)
• 9 The Future of Veterinary Nutraceutical Regulations (p.763)
• References (p.763)
• 1 Introduction (p.765)
• 2 FDA Perspective (p.766)
• 3 Inapplicability of DSHEA to Veterinary Products (p.766)
• 4 Feed Additives (p.767)
• 5 Nutraceuticals for Pets (p.767)
• 6 Safety Concerns (p.768)
• 7 Regulations in Canada (p.768)
• 8 Included and Excluded Products (p.769)
• 9 Labeling Guidance (p.769)
• 10 Manufacturing Requirements (p.770)
• 11 Reporting of Adverse Effects (p.770)
• 12 Compliance and Enforcement (p.770)
• 13 Concluding Remarks and Future Directions (p.770)
• References (p.771)
• 1 Introduction (p.772)
• 2 Guidelines for the Distinction Between Feed Materials, Feed Additives, and Veterinary Medicinal Products (p.773)
• 3 Nutraceuticals as Feed Material (p.774)
• 4 Nutraceuticals as Feed Additives (p.774)
• 5 Nutraceutical Properties Claimed on Animal Feed Labels (p.778)
• 6 Nutraceuticals as Veterinary Medicinal Products (VMPs) (p.778)
• 7 Concluding Remarks and Future Directions (p.781)
• References (p.783)
• 1 Introduction (p.785)
• 2 Historical Background (p.786)
• 3 Contribution of Livestock Sector in GDP (p.786)
• 4 Indian Market and Animal Health Nutrition: Current Trends (p.787)
• 5 Overview of Regulations of Other Countries (p.788)
• 6 Regulations (p.789)
• 7 Regulatory Requirements for Entry in India (p.790)
• 8 Product Evaluation (p.790)
• 9 The Benefits (p.791)
• 10 The Disadvantages (p.791)
• 11 Role of Government and Public Sector Institutes (p.791)
• 12 Concluding Remarks and Future Directions (p.791)
• References (p.792)
• 1 Introduction (p.793)
• 2 Classification (p.794)
• 3 Uses of Chinese Native Nutraceuticals (p.794)
• 4 Regulatory Guidelines of Nutraceuticals in China (p.796)
• 5 Concluding Remarks and Future Directions (p.798)
• References (p.798)
• 1 Introduction (p.800)
• 2 What Is and Is Not a Therapeutic Good in Australia (p.800)
• 3 What is a Complementary Medicine in Australia? (p.802)
• 4 What Is and Is Not a Therapeutic Product in New Zealand and How Are They Regulated? (p.802)
• 5 What is a Novel Food in Australia and New Zealand (p.803)
• 6 Concluding Remarks and Future Directions (p.804)
• References (p.804)
• 1 Introduction (p.805)
• 2 Applications Relating to Feed Hygiene Regulation (p.806)
• 3 Applications Relating to the Regulation on Placing on the Market and Feed Use (p.807)
• 4 Applications Relating to the Communiqué on Undesirable Substances in Animal Feed (p.807)
• 5 Applications Relating to the Regulation on the Official Control of Feed and Food (p.807)
• 6 Applications Relating to the Regulation on Feed Additives for Use in Animal Nutrition (p.807)
• 7 Concluding Remarks and Future Directions (p.812)
• References (p.812)
• 1 Introduction (p.813)
• 2 Regulation of Nutraceuticals (p.814)
• 3 Concluding Remarks and Future Directions (p.816)
• References (p.816)
• 1 Introduction (p.818)
• 2 Legislative Framework in South Africa (p.818)
• 3 General Control of Veterinary Nutraceuticals (p.821)
• 4 Concluding Remarks and Future Directions (p.823)
• References (p.823)
• Index (p.824)
• ... and 84 more chapters

🔗 Download Link:

Frequently bought together

Infectious Disease Management In Animal Shelters

HK$210.00

HK$210.00

Claim Offer